Linear TMC-95-based proteasome inhibitors

Journal of Medicinal Chemistry

Volumn 50, Issue 12, 2007, Pages 2842-2850

  Basse, Nicolas ^a   Piguel, Sandrine ^b   Papapostolou, David ^a   Ferrier Berthelot, Alexandra ^b   Richy, Nicolas ^b   Pagano, Maurice ^a   Sarthou, Pierre ^c   Sobczak Thépot, Joëlle ^c   Reboud Ravaux, Michele ^a   Vidal, Joëlle ^b  

^a INSTITUT JACQUES MONOD   (France)

^b Chimie et Photonique Moleculaires Rennes   (France)

^c CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; CYCLOPEPTIDE; PROTEINASE INHIBITOR; TMC 95A; TYROPEPTIN A; UNCLASSIFIED DRUG;

ARTICLE; CELL LINE; COLUMN CHROMATOGRAPHY; CONTROLLED STUDY; CULTURE MEDIUM; CYTOTOXICITY; DRUG DESIGN; DRUG MECHANISM; DRUG STRUCTURE; ENZYME INHIBITION; HUMAN; HUMAN CELL; PEPTIDE SYNTHESIS;

ANTINEOPLASTIC AGENTS; CATALYTIC DOMAIN; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; PEPTIDES, CYCLIC; PROTEASOME ENDOPEPTIDASE COMPLEX; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 34250806632     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0701324     Document Type: Article

References (46)

1. (a) Coux, O.; Tanaka, K.; Goldberg, A. L. Structure and functions of the 20S and 26S proteasomes Annu. Rev. Biochem. 1996, 65, 801-847.
2. (b) Ciechanover, A. The ubiquitin-proteasome pathway: on protein death and cell life. EMBO J. 1998, 17, 7151-7160.
3. Rock, K.; York, I. A.; Goldberg, A. L. Post-proteasomal antigen processing for major histocompatibility complex class I presentation. Nat. Immunol. 2004, 5, 670-677.
4. (a) Goldberg, A. L.; Rock, K. Not just research tools-proteasome inhibitors offer therapeutic promise. Nat. Med. 2002, 8, 338-340.
5. (b) Myung, J.; Kim, K. B.; Crews, C. M. The ubiquitin-proteasome pathway and proteasome inhibitors. Med. Res. Rev. 2001, 21, 245-273.
6. Adams, J., Ed. Proteasome Inhibitors in Cancer Therapy; Humana Press: Totowa, NJ, 2004.
7. Kisselev, A. F.; Goldberg, A. L. Proteasome inhibitors: from research tools to drug candidates. Chem. Biol. 2001, 8, 739-758.
8. Garcia-Echeverria, C. Peptide and peptide-like modulators of 20S proteasome enzymatic activity in cancer cells. Int. J. Pept. Res. Ther. 2006, 12, 49-64.
9. Groll, M.; Huber, R.; Potts, B. C. M. Crystal structures of salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of β-lactone ring opening and a mechanism for irreversible binding. J. Am. Chem. Soc. 2006, 128, 5136-5141 and references cited therein.
10. Schmidtke, G.; Holzhutter, H. G.; Bogyo, M.; Kairies, N.; Groll, M.; de Giuli, R.; Emch, S.; Groettrup, M. How an inhibitor of the HIV-I protease modulates proteasome activity. J. Biol. Chem. 1999, 274, 35734-35740.
11. (a) Furet, P.; Imbach, P.; Noorani, M.; Koeppler, J.; Laumen, K.; Lang, M.; Guagnano, V.; Fuerst, P.; Roesel, J.; Zimmermann, J.; Garcia-Echeverria, C. Entry into a new class of potent proteasome inhibitors having high antiproliferative activity by structure-based design. J. Med. Chem. 2004, 47, 4810-4813.
12. (b) Garcia-Echeverria, C.; Imbach, P.; France, D.; Furst, P.; Lang, M.; Noorani, A. M.; Scholz, D.; Zimmermann, J.; Furet, P. A new structural class of selective and non-covalent inhibitors of the chymotrypsin-like activity of the 20S proteasome. Bioorg. Med. Chem. Lett. 2001, 11, 1317-1319.
13. (c) Furet, P.; Imbach, P.; Fuerst, P.; Lang, M.; Noorani, M.; Zimmermann, J.; Garcia-Echeverria, C. Structure-based optimisation of 2-aminobenzylstatine derivatives: potent and selective inhibitors of the chymotrypsin-like activity of the human 20S proteasome. Bioorg. Med. Chem. Lett. 2002, 12, 1331-1334.
14. Kohno, J.; Koguchi, Y.; Nishio, M.; Nakao, K.; Kuroda, M.; Shimizu, R.; Ohnuki, T.; Komatsubara, S. Structures of TMC-95A-D: novel proteasome inhibitors from Apiospora montagnei sacc. TC 1093. J. Org. Chem. 2000, 65, 990-995.
15. Koguchi, Y.; Kohno, J.; Nishio, M.; Takahashi, K.; Okuda, T.; Ohnuki, T.; Komatsubara, S. TMC-95A, B, C, and D, novel proteasome inhibitors produced by Apiospora montagnei Sacc. TC 1093. Taxonomy, production, isolation, and biological activities. J. Antibiot. 2000, 53, 105-109.
16. (a) Groll, M.; Koguchi, Y.; Huber, R.; Kohno, J. Crystal structure of the 20 S proteasome:TMC-95A complex: a non-covalent proteasome inhibitor. J. Mol. Biol. 2001, 311, 543-548.
17. (b) Kaiser, M.; Groll, M.; Siciliano, C.; Assfalg-Machleidt, I.; Weyher, E.; Kohno, J.; Milbradt, A. G.; Renner, C.; Huber, R.; Moroder, L. Binding mode of TMC-95A analogues to eukaryotic 20S proteasome. ChemBioChem 2004, 5 (9), 1256-1266.
18. (a) Lin, S.; Danishefsky, S. J. The total synthesis of proteasome inhibitors TMC-95A and TMC-95B: discovery of a new method to generate cis-propenyl amides. Angew. Chem., Int. Ed. 2002, 41, 512-515.
19. (b) Lin, S.; Yang, Z. Q.; Kwok, B. H.; Koldobskiy, M.; Crews, C. M.; Danishefsky, S. J. Total synthesis of TMC-95A and -B via a new reaction leading to Z-enamides. Some preliminary findings as to SAR. J. Am. Chem. Soc. 2004, 126, 6347-6355.
20. Inoue, M.; Sakazaki, H.; Furuyama, H.; Hirama, M. Total synthesis of TMC-95A. Angew. Chem., Int. Ed. 2003, 42, 2654-2657.
21. (a) Albrecht, B. K.; Williams, R. M. A concise, total synthesis of the TMC-95A/B proteasome inhibitors. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 11949-11954.
22. (b) Albrecht, B. K.; Williams, R. M. A concise formal total synthesis of TMC-95A/B proteasome inhibitors. Org. Lett. 2003, 5 (2), 197-200.
23. Yang, Z.-Q.; Kwok, B. H. B.; Lin, S.; Koldobskiy, M. A.; Crews, C. M.; Danishefsky, S. J. Simplified synthetic TMC-95A/B analogues retain the potency of proteasome inhibitory activity. ChemBioChem 2003, 4, 508-513.
24. Kaiser, M.; Groll, M.; Renner, C.; Huber, R.; Moroder, L. The core structure of TMC-95A is a promising lead for reversible proteasome inhibition. Angew. Chem., Int. Ed. 2002, 41, 780-783.
25. Kaiser, M.; Siciliano, C.; Assfalg-Machleidt, I.; Groll, M.; Milbradt, A. G.; Moroder, L. Synthesis of a TMC-95A ketomethylene analogue by cyclization via intramolecular Suzuki coupling. Org. Lett. 2003, 5, 3435-3437.
26. Kaiser, M.; Milbradt, A. G.; Siciliano, C.; Assfalg-Machleidt, I.; Machleidt, W.; Groll, M.; Renner, C.; Moroder, L. TMC-95A analogues with endocyclic biphenyl ether group as proteasome inhibitors. Chem. Biodiversity 2004, 1, 161-173.
27. Groll, M.; Götz, M.; Kaiser, M.; Weyher, E.; Moroder, L. TMC-95-based inhibitor design provides evidence for the catalytic versatility of the proteasome. Chem. Biol. 2006, 13, 607-614.
28. Berthelot, A.; Piguel, S.; Le Dour, G.; Vidal, J. Synthesis of macrocyclic peptide analogues of proteasome inhibitor TMC-95A. J. Org. Chem. 2003, 68, 9835-9838.
29. Bodanszky, M.; Bodanszky, A. The Practice of Peptide Synthesis, 2nd ed.; Springer-Verlag: Berlin, 1994.
30. Sy, W.-W. Iodination of methoxyamphetamines with iodine and silver sulfate. Tetrahedron Lett. 1993, 34, 6223-6224.
31. Ishiyama, T.; Murata, M.; Miyaura, N. Palladium(0)-catalyzed cross-coupling reaction of alkoxydiboron with haloarenes: a direct procedure for arylboronic esters. J. Org. Chem. 1995, 60, 7508-7510.
32. Suzuki, A.; Brown, H. C. Organic Syntheses via Boranes. Suzuki Coupling; Aldrich Chemical Co.: Milwaukee, WI, 2003; p 20.
33. (a) Miyaura, N.; Suzuki, A. Palladium-catalyzed cross-coupling reactions of organoboron compounds. Chem. Rev. 1995, 95, 2457-2483.
34. (b) Lloyd-Williams, P.; Giralt, E. Atropisomerism, biphenyls and the Suzuki coupling: peptide antibiotics. Chem. Soc. Rev. 2001, 30, 145-157.
35. Hassan, J.; Sevignon, M.; Gozzi, C.; Schulz, E.; Lemaire, M. Aryl-aryl bond formation one century after the discovery of the Ullmann reaction. Chem. Rev. 2002, 102, 1359-1469.
36. (a) Wang, W.; Xiong, C.; Yang, J.; Hruby, V. J. Practical, asymmetric synthesis of aromatic-substituted bulky and hydrophobic tryptophan derivatives. Tetrahedron Lett. 2001, 42, 7717-7719.
37. (b) Wang, W.; Xiong, C.; Zhang, J.; Hruby, V. J. Practical, asymmetric synthesis of aromatic-substituted bulky and hydrophobic tryptophan and phenylalanine derivatives. Tetrahedron 2002, 58, 3101-3110.
38. Kaiser, M.; Milbradt, A.; Moroder, L. Synthesis of TMC-95A analogues. Structure based prediction of cyclisation propensities of linear precursors. Lett. Pept. Sci. 2002, 65-70.
39. (a) Semmelhack, M. F.; Helquist, P. M.; Jones, L. D. Synthesis with zerovalent nickel. Coupling of aryl halides with bis(1,5-cyclooctadiene) nickel(0). J. Am. Chem. Soc. 1971, 93, 5908-5910.
40. (b) Carbonnelle, A.-C.; Zamora, E. G.; Beugelmans, R.; Roussi, G. The first synthesis of simplified 16- and 17-membered ring macropolypeptides containing the phenyl-indole system of kistamycin and chloropeptin I, II. Tetrahedron Lett. 1998, 39, 4471-4472.
41. (c) Beugelmans, R.; Roussi, G.; Zamora, E. G.; Carbonnelle, A.-C. Synthetic studies towards western and eastern macropolypeptide subunits of kistamicin. Tetrahedron 1999, 55, 5089-5112.
42. Momose, I.; Umezawa, Y.; Hirosawa, S.; Iinuma, H.; Ikeda, D. Structure-based design of derivatives of tyropeptin A as the potent and selective inhibitors of mammalian 20S proteasome. Bioorg. Med. Chem. Lett. 2005, 15, 1867-1871.
43. Marastoni, M.; Baldisserotto, A.; Canella, A.; Gavioli, R.; De Risi, C.; Pollini, G. P.; Tomatis, R. Arecoline tripeptide inhibitors of proteasome. J. Med. Chem. 2004, 47, 1587-1590.
44. Basse, N.; Papapostolou, D.; Pagano, M.; Reboud-Ravaux, M.; Bernard, E.; Felten, A.-S.; Vanderesse, R. Development of lipopeptides for inhibiting 20S proteasomes. Bioorg. Med. Chem. Lett. 2006, 16, 3277-3281.
45. Lum, R. T.; Nelson, M. G.; Joly, A.; Horsma, A. G.; Lee, G.; Meyer, S. M.; Wick, M. M.; Schow, S. R. Selective inhibition of the chymotrypsin-like activity of the 20S proteasome by 5-methoxy-1-indanone dipeptide benzamides. Bioorg. Med. Chem. Lett. 1998, 8, 209-214.
46. Glenn, R. J.; Pemberton, A. J.; Royle, H. J.; Spademan, R. W.; Smith, E.; Rivett, A. J.; Sterverding, D. Trypanocidal effect of α′, β′-epoxyketones indicates that trypanosomes are particularly sensitive to inhibitors of proteasome trypsin-like activity. Int. J. Antimicrob. Agents 2004, 24, 286-289.